摘要
目的分析普拉克索+左旋多巴治疗帕金森病的临床疗效及安全性。方法在该院患者中选取2018年7月—2019年7月共120例帕金森病患者作为该次研究对象,以电脑随机的方法将患者分为两组,即对照组和实验组。对照组采用左旋多巴治疗,实验组采取普拉克索+左旋多巴联合治疗。比较两组患者的治疗效果,不良反应发生率,并请两组患者用焦虑/抑郁自评量表评分,比较两组患者的心理状态。结果实验组的治疗效果(93.33%)高于对照组(73.33%),差异有统计学意义(χ2=8.640,P<0.05);实验组的不良反应发生率(3.33%)均低于对照组不良反应发生率(13.33%),差异有统计学意义(χ2=3.920,P<0.05),实验组患者焦虑自评量表(SAS)、抑郁自评量(SDS)表得分分别为(45.2±4.3)分和(42.8±6.3)分,这两个表均明显低于对照组的(56.3±7.5)分和(58.1±3.9)分,差异有统计学意义(t=12.310、15.990,P<0.05)。结论在对帕金森病患者的治疗中采用普拉克索+左旋多巴联合治疗,可以提高患者的治疗效果,减少患者的不良反应发生率,在一定程度上减轻患者的心理负面情绪,在临床对帕金森病患者的治疗中具有推广价值。
Objective To analyze the clinical efficacy and safety of Praxox+levodopa in the treatment of Parkinson’s disease.Methods A total of 120 patients with Parkinson’s disease from July 2018 to July 2019 were selected as patients in the hospital.They were divided into two groups by computer random method,namely the control group and the experimental group.The control group was treated with levodopa,and the experimental group was treated with pramipexole plus levodopa.The treatment effect and the incidence of adverse reactions were compared between the two groups of patients,and the two groups were asked to score with the anxiety/depression self-rating scale to compare the psychological status of the two groups of patients.Results The therapeutic effect of experimental group(93.33%) was higher than that of control group(73.33%),the difference was statistically significant(χ2=8.640,P<0.05).The incidence of adverse reactions(3.33%) in experimental group was lower than that in control group(13.33%),the difference was statistically significant(χ2=3.920,P<0.05).The scores of the self-rating anxiety scale(SAS) and the self-depressing scale(SDS) of the experimental group were(45.2±4.3) points and(42.8±6.3) points,both tables are significantly lower than the control group’s(56.3±7.5) points and(58.1±3.9) points,the difference was statistically significant(t=12.310,15.990,P<0.05).Conclusion The combination of Praxo and levodopa in the treatment of patients with Parkinson’s disease can improve the treatment effect of the patient,reduce the incidence of adverse reactions,and reduce the patient’s psychological negative emotion to a certain extent.It has promotion value in the treatment of patients with Parkinson’s disease.
作者
张含颖
ZHANG Han-ying(Department of Neurology,Changle County People's Hospital,Weifang,Shandong Province,262400 China)
出处
《世界复合医学》
2020年第5期13-15,共3页
World Journal of Complex Medicine
